novobiocin and Cytomegalovirus-Infections

novobiocin has been researched along with Cytomegalovirus-Infections* in 3 studies

Other Studies

3 other study(ies) available for novobiocin and Cytomegalovirus-Infections

ArticleYear
Modulation of the frequency of human cytomegalovirus-induced chromosome aberrations by camptothecin.
    Virology, 1992, Volume: 189, Issue:1

    The effects of selected DNA repair inhibitors on the frequency of human cytomegalovirus (HCMV)-induced chromosome aberrations were evaluated in human peripheral blood lymphocytes (PBLs). Treatment of HCMV-infected PBLs with camptothecin (0.05 to 0.3 micrograms/ml), an inhibitor of topoisomerase I, for 30 hr resulted in a significant (P less than 0.01) synergistic enhancement of the frequency of HCMV-induced chromosome damage. On the other hand, a significant increase in the frequency of chromosome damage was not noted for infected PBLs treated with either 3-aminobenzamide (3-AB; 3 to 30 micrograms/ml), an inhibitor of poly(ADP-ribose) polymerase, or novobiocin (3 to 30 micrograms/ml), an inhibitor of topoisomerase II or excision repair processes, for 30 hr. Chromatid-type breaks and exchanges were the predominant type of chromosome aberrations observed in the HCMV-infected cells treated with camptothecin, suggesting that HCMV infection is associated with the induction of single-strand DNA breaks. Furthermore, these findings suggest that HCMV infection does not inflict direct DNA damage which is repaired through 3-AB- or novobiocin-sensitive pathways.

    Topics: Benzamides; Camptothecin; Cells, Cultured; Chromosome Aberrations; Cytomegalovirus Infections; DNA Repair; Dose-Response Relationship, Drug; Humans; Lymphocytes; Novobiocin; Poly(ADP-ribose) Polymerase Inhibitors

1992
In-vivo effect of novobiocin on primary cytomegalovirus infection.
    The Journal of antimicrobial chemotherapy, 1983, Volume: 12, Issue:5

    .5 mM of novobiocin completely suppresses the replication of human cytomegalovirus (HCMV) in vitro. Based on the evidence that murine cytomegalovirus (MCMV) titres were reduced in vitro by 60% with the same concentration of the drug, the in vivo antiviral activity of novobiocin has been tested in the murine model. The results showed that if treatment started before the infection virus was not isolated from parenchymal organs during treatment. Virus could be isolated 24 h after stopping treatment, but not from kidney or spleen.

    Topics: Animals; Cytomegalovirus; Cytomegalovirus Infections; Female; Mice; Mice, Inbred Strains; Novobiocin

1983
Cytomegalic inclusion disease treated with idoxuridine and novobiocin.
    Lancet (London, England), 1973, Jan-06, Volume: 1, Issue:7793

    Topics: Cytomegalovirus Infections; Humans; Idoxuridine; Infant, Newborn; Male; Novobiocin

1973